Stockscreener 앱 받기
9.87
0.92%
0.09
시간 외 거래:
9.87
전일 마감가:
$9.78
열려 있는:
$9.82
하루 거래량:
1.43M
Relative Volume:
0.89
시가총액:
$3.10B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-14.50
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
-4.08%
1개월 성능:
+1.33%
6개월 성능:
+37.47%
1년 성능:
+13.45%
1일 변동 폭
$9.75
$9.98
1주일 범위
$9.56
$10.30
52주 변동 폭
$6.685
$10.68
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
9.87 | 3.05B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
143.26 | 63.58B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.88 | 43.58B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.20 | 40.83B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.63 | 23.07B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
432.69 | 19.61B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
What analyst consensus says on Amneal Pharmaceuticals Inc. stockTrade Volume Report & Free Technical Confirmation Trade Alerts - newser.com
What analysts say about Amneal Pharmaceuticals Inc stockMarket Correction Analysis & Learn to Trade Without Fear of Loss - earlytimes.in
Chart based exit strategy for Amneal Pharmaceuticals Inc.Earnings Beat & Safe Entry Zone Identification - newser.com
Amneal Pharmaceuticals Highlights Innovation and Access to Medication to Treat Patients - WJLA
What moving averages say about Amneal Pharmaceuticals Inc.2025 Earnings Surprises & Daily Stock Trend Reports - newser.com
Why Amneal Pharmaceuticals Inc. stock is considered a top pickMarket Movement Recap & High Accuracy Buy Signal Tips - newser.com
How to manage a losing position in Amneal Pharmaceuticals Inc.2025 Retail Activity & AI Forecasted Stock Moves - newser.com
Will Amneal Pharmaceuticals Inc. see short term momentumWeekly Trading Summary & Weekly High Potential Stock Alerts - newser.com
What MACD and RSI say about Amneal Pharmaceuticals Inc.Oil Prices & Accurate Technical Buy Alerts - newser.com
Assessing Amneal Pharmaceuticals (AMRX) Valuation After BLA Submission and Eased Regulatory Risks - Sahm
What to expect from Amneal Pharmaceuticals Inc. in the next 30 daysJuly 2025 Closing Moves & AI Forecasted Stock Moves - newser.com
Will Amneal Pharmaceuticals Inc. stock benefit from automationVolume Spike & Safe Capital Growth Tips - newser.com
Amneal seeks FDA nod for generic targeting Xolair marketed by Roche and Novartis - MSN
Amneal Pharmaceuticals Hits New 52-Week High of $10.67 - Markets Mojo
FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
How Amneal’s (AMRX) Biosimilar XOLAIR Application Could Shape Its Specialty Pharma Ambitions - Sahm
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga
Will Amneal Pharmaceuticals Inc. price bounce be sustainable2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
When is the best time to exit Amneal Pharmaceuticals Inc.July 2025 Outlook & Weekly High Return Stock Opportunities - newser.com
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Biosimilar XOLAIR FDA Submission – Learn Why - Yahoo Finance
Technical analysis overview for Amneal Pharmaceuticals Inc. stockEarnings Beat & Risk Controlled Swing Trade Alerts - newser.com
A Look at Amneal Pharmaceuticals’s Valuation After XOLAIR Biosimilar Submissions and Recent Analyst Upgrades - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Receives Hold (C) Rating from Weiss Ratings - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR® Biosimilar, Targets Multi-Billion-Dollar Market - MSN
Amneal Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? - sharewise.com
Does Amneal Pharmaceuticals Still Offer Value After 36% Surge and New Product Approvals in 2025? - Sahm
Amneal Pharmaceuticals (NASDAQ:AMRX) Increases 6.9% This Week, Taking Three-year Gains to 420% - 富途牛牛
Amneal Pharmaceuticals, Inc. (AMRX) Rating Update: Analysts See 18.48% Upside Potential - DirectorsTalk Interviews
Measuring Amneal Pharmaceuticals Inc.’s beta against major indicesJuly 2025 Selloffs & Low Volatility Stock Recommendations - newser.com
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus - Nasdaq
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab) - Business Wire
Applying Wyckoff theory to Amneal Pharmaceuticals Inc. stockJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
Reversal indicators forming on Amneal Pharmaceuticals Inc. stockEarnings Trend Report & Expert Approved Momentum Ideas - newser.com
Is it time to cut losses on Amneal Pharmaceuticals Inc.Quarterly Portfolio Review & Proven Capital Preservation Methods - newser.com
Using Python tools to backtest Amneal Pharmaceuticals Inc. strategies2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
Sentiment analysis tools applied to Amneal Pharmaceuticals Inc.Portfolio Risk Summary & High Win Rate Trade Tips - newser.com
How to read the order book for Amneal Pharmaceuticals Inc.Trade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Will breakout in Amneal Pharmaceuticals Inc. lead to full recoveryGap Down & Comprehensive Market Scan Insights - newser.com
Amneal Pharmaceuticals Hits New 52-Week High of $10.43 - Markets Mojo
Is Amneal Pharmaceuticals Inc. stock cheap compared to fundamentalsEarnings Growth Report & Safe Entry Zone Identification - newser.com
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
5.75%
자본화:
|
볼륨(24시간):